CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eurocine Vaccines AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eurocine Vaccines AB
Nanna Svartz vag 4
Phone: +46 850884592p:+46 850884592 SOLNA, 171 65  Sweden Ticker: EUCIEUCI
Business Summary
Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Company’s uses its clinically validated technology Endocine. In addition, the Company’s primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Pierre A.Morgon 57 5/14/2019 12/17/2013
President, Chief Executive Officer, Director HansArwidsson 63 6/19/2019 1/1/2004
Head of Preclinical Development KarlLjungberg 6/1/2019 6/1/2019
3 additional Officers and Directors records available in full report.

Business Names
Business Name
EUCI
Eurocine Vaccines AB
Eurocine Vaccines AB (publ)

General Information
Number of Employees: 3 (As of 12/31/2020)
Outstanding Shares: 344,410,497 (As of 1/3/2024)
Shareholders: 4,516
Stock Exchange: AKT
Fax Number: +46 850884591


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024